Jaguar Health

176 articles with Jaguar Health

• Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community

  5/19/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the Company recently launched a new social media channel for stakeholders and the Companys growing community of followers. The Jaguar Health Community Instagram page will serve as a central social media communications hub

• Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs

  5/18/2021

  Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved

• Jaguar Health, Inc. Reports 2021 First Quarter Financial Results

  5/17/2021

  First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials business updates

• Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote

  5/14/2021

  Jaguar Health, Inc. announced that its Annual Meeting of Stockholders held on May 13, 2021 was adjourned due to a lack of quorum.

• Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates

  5/11/2021

  Jaguar Health, Inc. today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.

• Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan

  4/29/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering.

• Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting

  4/29/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc. Jaguars wholly owned subsidiary, and Napos collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4, 2021

• REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary

  4/21/2021

  Jaguar Health, Inc. issued a reminder about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company, that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A., Jaguar's wholly owned Italian subsidiary.

• Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary

  4/19/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the Company founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern

• Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs

  4/15/2021

  Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV

• Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting

  4/14/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea by Napo Pharmaceuticals, Inc.

• Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC

  4/8/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment to the March 24, 2020 equity purchase agreement Equity Purchase Agreement with Oasis Capital, LLC

• Jaguar Health Promotes Carol Lizak to Chief Financial Officer

  4/6/2021

  Jaguar Health, Inc. ) announced today that the Company has promoted Carol Lizak, an accomplished financial executive, to the expanded role of chief financial officer.

• Jaguar Health Reports 2020 Financial Results and Business Updates

  3/31/2021

  Jaguar Health, Inc. reported consolidated financial results for the year ended December 31, 2020.

• Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary

  3/30/2021

  Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer

• Jaguar Health Announces Winner of International Day of Forests Contest

  3/22/2021

  New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV

• Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy

  3/15/2021

  Napo EU will serve as the foundation of the Companys efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population In honor of International Day of Forests, Company is conducting a survey contest to raffle off a signed print of an original painting of a Jaguar by Anthony J. Conte - link to entry form appears below

• Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

  3/9/2021

  No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after recovery SAN FRANCISCO, CA / ACCESSWIRE / March 9, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has signed the definitive

• Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream

  3/5/2021

  Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company has entered a binding agreement of terms (the "Term Sheet") for a third non-dilutive royalty financing transaction, pursuant to which Jaguar would sell to the lender for an aggregate purchase price of $5 million

• Jaguar Health Launches Website for Napo EU

  2/23/2021

  Site contains links to information about post-COVID-19 long-hauler syndrome An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in long-hauler COVID-19 recovery patients in Europe SAN F